PCSK9 and familial hyperaldosteronism: To determine whether the suppressed IFN signature is also observed in monocytes of FH patients, we performed RNA-seq of peripheral monocytes derived from FH patients before and after lipid-lowering treatment by ezetimibe, statins, and/or PCSK9 antibodies, as well as age and gender-matched healthy donors (Supplementary Tables 1, 2).